New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
11:44 EDTPCLN, GILDStocks with call strike movement; PCLN GILD
Priceline (PCLN) July 1490 call option implied volatility increased 6% to 35, Gilead (GILD) August 82.5 call option implied volatility increased 5% to 82.5 according to IVolatility.
News For PCLN;GILD From The Last 14 Days
Check below for free stories on PCLN;GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
08:07 EDTGILDFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
September 22, 2014
12:11 EDTPCLNTripAdvisor sinks after data breach at just acquired unit
Shares of TripAdvisor (TRIP) are falling after the company's Viator unit reported today that it had experienced a data breach. TripAdvisor operates websites with information about travel destinations and flights. Viator, whose acquisition by TripAdvisor closed in August, features more than 20,000 bookable tours and attractions and more than 600,000 reviews, photos, and videos submitted by travelers, TripAdvisor has stated. WHAT'S NEW: Viator stated that it was informed on September 2 that unauthorized charges had been made on a number of its customers' credit cards. The data breach that the unit experienced could affect payment card data that was used to make bookings through the unit's websites, according to Viator. Moreover, customers' email addresses and their passwords and user names for Viator may have also been compromised. About 880,000 customers may have had their payment card information compromised, while about 560,000 customers' Viator account information and e-mail addresses may have been affected, the unit reported. WHAT'S NOTABLE: The breach at Viator comes in the wake of large data breaches at a number of bellwether companies in recent months, including JPMorgan (JPM) and Home Depot (HD). Late last year tens of thousands of payment card data was stolen from Target (TGT). PRICE ACTION: In late morning trading, TripAdvisor sank 5.5% to $93. Others names in the online travel space are falling, with Priceline.com down 3% and Expedia down 2%. :the
09:15 EDTGILDIntercept recent weakness a buying opportunity, says Summer Street
Subscribe for More Information
September 19, 2014
11:26 EDTGILDStocks with call strike movement; TSLA GILD
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
06:25 EDTGILDGilead granted marketing aurhotization from European Commission for Zydelig
Subscribe for More Information
06:11 EDTGILDGilead price target raised to $139 from $111 at Citigroup
Citigroup raised its price target for Gilead shares to $139 saying management looks "very optimistic" that FY15 hepatitis C treatment volumes could be up substantially over FY14 rates globally. Citi also expects recent buybacks to boost Q4 earnings substantially and that future stock buybacks will drive appreciation. The firm keeps a Buy rating on Gilead.
September 18, 2014
12:12 EDTGILDStocks with call strike movement; PIR GILD
Subscribe for More Information
08:17 EDTGILDGilead trial failure not material, says FBR Capital
Subscribe for More Information
September 17, 2014
11:52 EDTGILDStocks with call strike movement; X GILD
Subscribe for More Information
06:04 EDTGILDGilead's simtuzumab Phase 2 study for pancreatic cancer does not meet endpoint
Gilead announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2, in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, the addition of simtuzumab to gemcitabine did not significantly increase progression-free survival compared to placebo plus gemcitabine. There was no difference in adverse events between patients taking simtuzumab versus placebo. Simtuzumab is being evaluated in several ongoing Phase 2 trials, including for advanced colorectal cancer, myelofibrosis, as monotherapy for idiopathic pulmonary fibrosis, and for liver fibrosis. Other agents in Gileadís oncology pipeline are currently being evaluated in clinical trials for the treatment of pancreatic cancer.
September 15, 2014
11:56 EDTGILDStocks with call strike movement; MU GILD
Subscribe for More Information
10:52 EDTGILDGilead heading for a test of support, levels to watch
The shares are down 2% to $101.54 at time of writing, putting the shares on track for a retest of the 30-day moving average at $101.21. A breakdown below that level would indicate a pickup in negative price momentum, with next support at $96.57, the 50-day moving average. A bounce from the 30-day would meet resistance at $106.93, the 10-day moving average.
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA RSH YHOO GILD TWTR AVNR NFLX BAC C
06:34 EDTGILDMylan signs agreement with Gilead
Mylan (MYL) announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences (GILD), under which Mylan has been licensed the non-exclusive rights to manufacture and distribute sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir in 91 developing countries. Sofosbuvir is marketed by Gilead under the brand name Sovaldi. The countries within the agreement account for more than 100M people living with hepatitis C globally representing 54% of the total global infected population. Under the licensing agreement, Mylan will receive a technology transfer enabling the company to manufacture low-cost versions of the medicines for developing markets.
06:31 EDTGILDGilead announces licensing agreements with seven pharmaceutical companies
Subscribe for More Information
September 12, 2014
14:56 EDTGILDGilead mentioned cautiously at ISI Group
September 11, 2014
11:58 EDTGILDStocks with call strike movement; DDD GILD
Subscribe for More Information
September 9, 2014
13:58 EDTPCLNStarbucks, Groupon, OpenTable apps among those to integrate Apple Pay
Subscribe for More Information
09:34 EDTGILDGilead recently started cutting Sovaldi pricing by 8%, says Cleveland Research
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use